Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
NCT00200668 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL
Last updated 2008-06-09
Summary
Comparison between FDG-PET and MRI for the assessment of response to intensive chemotherapy in multiple myeloma patients.
Conditions
Interventions
- DRUG
-
FDG = fluorodeoxyglucose
Sponsors & Collaborators
-
Nantes University Hospital
lead OTHER
Principal Investigators
-
Olivier Couturier, MD · Nantes University Hospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-03-31
- Completion
- 2006-12-31
Countries
- France
Study Locations
More Related Trials
-
Imaging in MGUS, SMM and MM
NCT01237054 ·Status: COMPLETED ·Phase: PHASE2
-
Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma
NCT04561492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations
NCT02858167 ·Status: COMPLETED ·Phase: NA
-
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
NCT06659276 ·Status: RECRUITING
-
MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma
NCT02733887 ·Status: UNKNOWN ·Phase: NA
-
99mTc-CNDG Injection in the Diagnosis of Malignant Tumors
NCT06030817 ·Status: RECRUITING ·Phase: NA
-
Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma
NCT00775957 ·Status: TERMINATED
-
Imaging Studies and the Development of Multiple Myeloma
NCT01571726 ·Status: WITHDRAWN ·Phase: PHASE2
-
Imaging Young Myeloma (IMAgerie JEune Myélome)
NCT01309334 ·Status: COMPLETED ·Phase: PHASE3
-
89Zr-labeled NY008 PET Imaging in Patients
NCT05655676 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
NCT06852807 ·Status: RECRUITING
-
FDG PET Imaging in Diagnosing Patients With Glioblastoma
NCT02885272 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
NCT06684028 ·Status: RECRUITING ·Phase: NA
-
FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)
NCT04349358 ·Status: RECRUITING ·Phase: NA
-
PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?
NCT00628940 ·Status: COMPLETED ·Phase: PHASE1
-
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
NCT05392205 ·Status: COMPLETED ·Phase: NA
-
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
NCT04272658 ·Status: RECRUITING
-
To Compare the Clinical Application of 18F-LNC1007 Injection PET/CT and 18F-FDG PET/CT
NCT06205888 ·Status: NOT_YET_RECRUITING
-
C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT
NCT01691300 ·Status: COMPLETED ·Phase: NA
-
Radionecrosis and FDG PET
NCT02391246 ·Status: UNKNOWN
-
Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner
NCT05381077 ·Status: UNKNOWN ·Phase: NA
-
A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging
NCT06834412 ·Status: RECRUITING ·Phase: NA
-
MPDL3280A-imaging-IST-UMCG
NCT02453984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
NCT04525612 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Comparison of FDG and FAPI in Patients With Various Types of Cancer
NCT04416165 ·Status: RECRUITING ·Phase: NA